Finland· FI-REL-REL54661
Reblozyl
A luspatercept product containing luspatercept, registered in Finland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Luspatercept is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA06 (luspatercept), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 10 of them publish a price we can compare per daily dose
Luspatercept · ATC B03XA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Luspatercept
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Finland (FI)
- ATC code
- B03XA06
- ATC class
- Luspatercept
- Defined daily dose
- 3.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Luspatercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesReblozylCelgene Corporation
- CanadaREBLOZYLBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandReblozyl 25 mg, Pulver zur Herstellung einer InjektionslösungBristol-Myers Squibb SA
- CzechiaREBLOZYLBristol-Myers Squibb Pharma EEIG, Dublin
- SpainREBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLEBristol-Myers Squibb Pharma Eeig
- BelgiumReblozyl 25 mgBristol-Myers Squibb Pharma
- FranceREBLOZYL 25 mg, poudre pour solution injectableBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandReblozyl 25 mg powder for solution for injectionBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Reblozyl
- Liechtenstein · Reblozyl
- Norway · Reblozyl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6b2ff6f6-0d62-47d3-8402-d274ffcd85e1 GET /v1/drugs/6b2ff6f6-0d62-47d3-8402-d274ffcd85e1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "3.33",
"form": "injektiokuiva-aine, liuosta varten",
"route": "Ihon alle",
"ddd_unit": "mg",
"strength": "75 mg",
"atc_label": "luspatersepti",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/20/1452/002",
"fimea_rel_id": "REL54661",
"authorised_at": "2020-06-25"
}See everything about luspatercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.